AORTIC AND SUPERIOR MESENTERIC ARTERY THROMBOSIS IN ANTITHROMBIN III DEFICIENCY-DIAGNOSTIC AND THERAPEUTIC CHALLENGES IN CONSERVATIVE MANAGEMENT

  • Surla Dimitrije Clinical Hospital Center Zemun, Department of general surgery, Belgrade, Serbia
  • Marija Nikolić Clinical Hospital Center Zemun, Department of general surgery, Belgrade, Serbia
  • Nemanja Trifunović Clinical Hospital Center Zemun, Department of general surgery, Belgrade, Serbia
  • Milica Stojadinović University Clinical Center of Serbia, Center for Radiology and Magnetic Resonance, Belgrade, Serbia
Keywords: abdominal aorta thrombosis, superior mesenteric artery thrombosis, antithrombin III deficiency, conservative treatment, anticoagulation therapy

Abstract


Introduction: Thrombosis of large arterial vessels, such as the abdominal aorta and superior mesenteric artery, is a rare but serious condition that requires timely diagnosis and appropriate management. One of the risk factors is antithrombin III (AT III) deficiency, a rare coagulation disorder that increases the likelihood of thrombosis. While arterial thromboses are less common than venous ones, they can have significant clinical consequences.

Case report: We present the case of a 39-year-old woman hospitalized due to sudden abdominal pain. Diagnostic imaging, including a contrast-enhanced CT scan of the abdomen and pelvis and CT angiography, revealed thrombosis of the distal abdominal aorta and superior mesenteric artery. Laboratory testing confirmed low AT III levels, while tests for hereditary thrombophilias were negative, suggesting a likely acquired deficiency.

The patient was treated conservatively with AT III concentrate, low-molecular-weight heparin, and oral anticoagulation, alongside regular INR monitoring. Therapy was complemented with cardioprotective and gastroprotective medications, as well as physical rehabilitation. During hospitalization, the patient remained hemodynamically stable, and symptoms gradually resolved. Follow-up imaging after several months demonstrated complete recanalization of the affected vessels. Long-term monitoring over two years confirmed stable clinical status and absence of recurrent thrombosis.

Conclusion: This case highlights the importance of early diagnosis, identification of the underlying cause, and carefully implemented conservative management in patients with AT III deficiency. It demonstrates that even in extensive arterial thrombosis, conservative management can preserve organ function and achieve a favorable outcome without the need for surgical intervention.

References

Gindele R, Selmeczi A, Oláh Z, Ilonczai P, Pfliegler G, Marján E, et al. Clinical and laboratory characteristics of antithrombin deficiencies: a large cohort study from a single diagnostic center. Thromb Res. 2017;160:119–128. doi: 10.1016/j.thromres.2017.10.023.

Corral J, Vicente V. Puzzling questions on antithrombin: diagnostic limitations and real incidence in venous and arterial thrombosis. Thromb Res. 2015;135(6):1047–8. doi: 10.1016/j.thromres.2015.04.012.

Schwartz RS, Bauer KA, Rosenberg RD, Kavanaugh EJ, Davies DC, Bogdanoff DA. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group.. Am J Med. 1989;87(3B):53S–60S. doi: 10.1016/0002-9343(89)80533-9.

Roberts JC, von Drygalski A, Zhou JY, Rodgers GM, Ansteatt K, Tarantino MD. Five challenging cases of hereditary antithrombin deficiency characterized by thrombosis or complicated pregnancy. J Blood Med. 2022;13:611–8. doi: 10.2147/JBM.S365996.

Rojnik T, Sedlar N, Turk N, Kastrin A, Debeljak M, Božič Mijovski M. Comparison of antithrombin activity assays in detection of patients with heparin binding site antithrombin deficiency: systematic review and meta-analysis. Sci Rep. 2023;13(1):16734. doi: 10.1038/s41598-023-43941-x.

von Blohn G, Hellstern P, Köhler M, Scheffler P, Wenzel E. Clinical aspects of acquired antithrombin III deficiency. Behring Inst Mitt. 1986;(79):200–15. German.

Ehrhardt JD Jr, Boneva D, McKenney M, Elkbuli A. Antithrombin deficiency in trauma and surgical critical care. J Surg Res. 2020;256:536–42. doi: 10.1016/j.jss.2020.07.010.

Farrell DH, McConnell KM, Zilberman-Rudenko J, Behrens B, Mcloud S, Cook MR, et al. Antithrombin III levels and outcomes among patients with trauma. JAMA Netw Open. 2024;7(8):e2427786. doi: 10.1001/jamanetworkopen.2024.27786.

Tormene D, Noventa F, Campello E, Gavasso S, Marobin M, Turatti G, et al. The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study. Intern Emerg Med. 2021;16(4):997–1003. doi: 10.1007/s11739-021-02656-5.

Englisch C, Königsbrügge O, Nopp S, Moik F, Quehenberger P, Preusser M, et al. Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer. Int J Mol Sci. 2022;23(24):15770. doi: 10.3390/ijms232415770.

Rodgers GM, Mahajerin A. Antithrombin therapy: current state and future outlook. Clin Appl Thromb Hemost. 2023;29:10760296231205279. doi: 10.1177/10760296231205279.

Published
2025/11/28
Section
Case report